218 related articles for article (PubMed ID: 26633585)
21. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Zheng W; Gao Y; Ke X; Zhang W; Su L; Ren H; Lin N; Xie Y; Tu M; Liu W; Ping L; Ying Z; Zhang C; Deng L; Wang X; Song Y; Zhu J
BMC Cancer; 2018 Sep; 18(1):910. PubMed ID: 30241515
[TBL] [Abstract][Full Text] [Related]
22. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
[TBL] [Abstract][Full Text] [Related]
23. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients.
Wang L; Xia ZJ; Huang HQ; Lu Y; Zhang YJ
Int J Hematol; 2012 Nov; 96(5):617-23. PubMed ID: 22983648
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
26. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
[TBL] [Abstract][Full Text] [Related]
27. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
[TBL] [Abstract][Full Text] [Related]
28. Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients.
Liu Y; Xue K; Xia Z; Jin J; Wang J; Sun H; Lv F; Liu X; Cao J; Hong X; Guo Y; Ma X; Zhang Q
Cancer Med; 2020 Aug; 9(15):5400-5405. PubMed ID: 32519518
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
Tse E; Kwong YL
Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
[TBL] [Abstract][Full Text] [Related]
30. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
[TBL] [Abstract][Full Text] [Related]
31. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
[TBL] [Abstract][Full Text] [Related]
32. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
33. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
Kim SJ; Yoon DH; Jaccard A; Chng WJ; Lim ST; Hong H; Park Y; Chang KM; Maeda Y; Ishida F; Shin DY; Kim JS; Jeong SH; Yang DH; Jo JC; Lee GW; Choi CW; Lee WS; Chen TY; Kim K; Jung SH; Murayama T; Oki Y; Advani R; d'Amore F; Schmitz N; Suh C; Suzuki R; Kwong YL; Lin TY; Kim WS
Lancet Oncol; 2016 Mar; 17(3):389-400. PubMed ID: 26873565
[TBL] [Abstract][Full Text] [Related]
34. A prognostic model based on pretreatment platelet lymphocyte ratio for stage IE/IIE upper aerodigestive tract extranodal NK/T cell lymphoma, nasal type.
Wang KF; Chang BY; Chen XQ; Liu PP; Wuxiao ZJ; Wang ZH; Li S; Jiang WQ; Xia ZJ
Med Oncol; 2014 Dec; 31(12):318. PubMed ID: 25377661
[TBL] [Abstract][Full Text] [Related]
35. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type.
Wu X; Li P; Zhao J; Yang X; Wang F; Yang YQ; Fang F; Xu Y; Zhang H; Wang WY; Yi C
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):619-25. PubMed ID: 18790372
[TBL] [Abstract][Full Text] [Related]
36. Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
Yamaguchi M; Takata K; Yoshino T; Ishizuka N; Oguchi M; Kobayashi Y; Isobe Y; Ishizawa K; Kubota N; Itoh K; Usui N; Miyazaki K; Wasada I; Nakamura S; Matsuno Y; Oshimi K; Kinoshita T; Tsukasaki K; Tobinai K
Cancer Sci; 2014 Nov; 105(11):1435-41. PubMed ID: 25181936
[TBL] [Abstract][Full Text] [Related]
37. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
[TBL] [Abstract][Full Text] [Related]
38. Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.
Liu X; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Qi SN; Yang Y; Li YX
JAMA Netw Open; 2019 Mar; 2(3):e190194. PubMed ID: 30821826
[TBL] [Abstract][Full Text] [Related]
39. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
Liang R; Gao GX; Chen JP; Wang JS; Wang XM; Zeng Y; Bai QX; Zhang T; Yang L; Dong BX; Gu HT; Shu MM; Hao CX; Wang JH; Zhang N; Chen XQ
Hematol Oncol; 2017 Dec; 35(4):619-629. PubMed ID: 27723108
[TBL] [Abstract][Full Text] [Related]
40. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma.
Tsai HJ; Lin SF; Chen CC; Chen TY; Su WC; Hwang WL; Lin JC; Chiou TJ; Kao WY; Chiu CF; Chang YF; Chang JS; Chang MC; Su IJ
Eur J Haematol; 2015 Feb; 94(2):130-7. PubMed ID: 24957163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
